Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events
The ONTARGET Investigators
- 10 Apr, 2008
This supplementary material requires a subscription.
Already a print subscriber? Activate your online access
Not a Subscriber?
Get full access to NEJM Online now with a FREE TRIAL!
Or, purchase access to this
supplementary material for $10
